Background Malaria in pregnancy has major impacts on mother and child health. To
complement existing interventions, such as intermittent preventive treatment and use of …

Background PRIMVAC is a VAR2CSA-derived placental malaria vaccine candidate aiming
to prevent serious clinical outcomes of Plasmodium falciparum infection during pregnancy …

In areas where Plasmodium falciparum transmission is endemic, clinical immunity against
malaria is progressively acquired during childhood and adults are usually protected against …

Placental malaria caused by Plasmodium falciparum is a major cause of mortality and
severe morbidity. Clinical testing of a soluble protein-based vaccine containing the parasite …

Pregnant women are susceptible to malaria during pregnancy. Plasmodium falciparum,
which sequesters in the placenta, causes the greatest disease, contributing significantly to …

Understanding of the biological basis for susceptibility to malaria in pregnancy was recently
advanced by the discovery that erythrocytes infected with Plasmodium falciparum …

Placental malaria (PM) due to Plasmodium falciparum is a major cause of maternal, fetal
and infant mortality, but the mechanisms of pathogenesis and protective immunity are …

Background. How antimalarial antibodies are acquired and maintained during pregnancy
and boosted after reinfection with Plasmodium falciparum and Plasmodium vivax is …

Background Apical Membrane Antigen 1 (AMA1), a polymorphic merozoite surface protein,
is a leading blood-stage malaria vaccine candidate. This is the first reported use in humans …

Placental malaria is caused by Plasmodium falciparum–infected erythrocytes that bind to
placental tissue. Binding is mediated by VAR2CSA, a parasite antigen coded by the var …